Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables.
active surveillance
biomarker
microRNA
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
20
04
2021
revised:
12
05
2021
accepted:
14
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Active surveillance (AS) has evolved as a strategy alternative to radical treatments for very low risk and low-risk prostate cancer (PCa). However, current criteria for selecting AS patients are still suboptimal. Here, we performed an unprecedented analysis of the circulating miRNome to investigate whether specific miRNAs associated with disease reclassification can provide risk refinement to standard clinicopathological features for improving patient selection. The global miRNA expression profiles were assessed in plasma samples prospectively collected at baseline from 386 patients on AS included in three independent mono-institutional cohorts (training, testing and validation sets). A three-miRNA signature (
Identifiants
pubmed: 34069838
pii: cancers13102433
doi: 10.3390/cancers13102433
pmc: PMC8157371
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : ED12162
Organisme : Fondazione Antonio Carlo Monzino
ID : N.A.
Références
Nat Rev Genet. 2012 Mar 13;13(4):271-82
pubmed: 22411466
Eur Urol. 2017 Oct;72(4):542-543
pubmed: 27842723
Oncol Lett. 2016 Jul;12(1):269-274
pubmed: 27347136
Eur Urol. 2014 Jun;65(6):1046-55
pubmed: 24439788
BJU Int. 2020 Sep;126(3):373-378
pubmed: 32367635
Urol Oncol. 2019 May;37(5):297.e9-297.e17
pubmed: 30777394
Oncotarget. 2017 May 31;8(48):83523-83538
pubmed: 29137361
PLoS One. 2014 Jun 03;9(6):e98597
pubmed: 24893170
Eur Urol. 2021 Apr;79(4):456-465
pubmed: 32631746
Nat Rev Urol. 2021 Apr;18(4):197-208
pubmed: 33623103
Mol Cancer. 2016 May 18;15(1):41
pubmed: 27189160
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Int J Biol Markers. 2002 Apr-Jun;17(2):148-51
pubmed: 12113584
Semin Cancer Biol. 2017 Jun;44:132-140
pubmed: 28344166
Curr Opin Urol. 2017 May;27(3):225-230
pubmed: 28267056
Oncol Lett. 2017 Jan;13(1):315-320
pubmed: 28123561
J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143
pubmed: 33545689
Anal Biochem. 2014 Sep 15;461:7-9
pubmed: 24892985
Eur Urol Oncol. 2019 May;2(3):277-285
pubmed: 31200842
J Urol. 2018 Jun;199(6):1475-1481
pubmed: 29246734
Prostate Cancer Prostatic Dis. 2017 Sep;20(3):339-342
pubmed: 28417979
Int J Cancer. 2020 Feb 15;146(4):1164-1173
pubmed: 31304978
Eur Urol. 2018 Sep;74(3):357-368
pubmed: 29937198
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6119-6130
pubmed: 31364112
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
Nat Rev Urol. 2016 Mar;13(3):151-67
pubmed: 26813955
J Clin Epidemiol. 2004 Dec;57(12):1262-70
pubmed: 15617952
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur Urol. 2017 Sep;72(3):448-454
pubmed: 27889277
J Urol. 2015 Aug;194(2):350-6
pubmed: 25747105
Clin Cancer Res. 2019 Jul 1;25(13):3887-3895
pubmed: 30814109
Tumori. 2017 Sep 18;103(5):464-474
pubmed: 28623636
Br J Cancer. 2016 Jun 28;115(1):1-4
pubmed: 27351381